Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

BACKGROUND: The incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest that the yearly number of deaths in Western Europe due to MPM will increase until 2020. Despite progress in chemo- and in multimodality therapy, MPM remains a disease wi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Belyanskaya, Larisa L, Marti, Thomas M, Hopkins-Donaldson, Sally, Kurtz, Stefanie, Felley-Bosco, Emanuela, Stahel, Rolf A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2007
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2134932/
https://ncbi.nlm.nih.gov/pubmed/17953743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-6-66
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak